DeepMed Research

University of Oxford

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1096-01-01

Employees: 10K

Market Cap: -

Website: http://www.ox.ac.uk

Clinical Trials

Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects

Phase 1

Completed

Conditions: Drug Combination
Pharmacokinetics
Healthy

Interventions: Drug: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
Drug: PQ and DHA-PQP and PQ
Drug: DHA-PQP

First Posted Date: 2015-10-05

Last Posted Date: 2017-05-31

Lead Sponsor: University of Oxford

Target Recruit Count: 16

Registration Number: NCT02568098

Locations: 🇹🇭
Faculty of Tropical Medicine, Bangkok, Thailand

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

Phase 1

Completed

Conditions: Hepatitis C Infection

Interventions: Biological: AdCh3NSmut1
Biological: MVA-NSmut

First Posted Date: 2015-10-05

Last Posted Date: 2018-10-11

Lead Sponsor: University of Oxford

Target Recruit Count: 20

Registration Number: NCT02568332

Locations: 🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇮🇪
St James's Hospital, Dublin, Ireland

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

Phase 2

Completed

Conditions: Relapsed Ewing Sarcoma
Refractory Ewing Sarcoma

Interventions: Drug: Linsitinib

First Posted Date: 2015-09-11

Last Posted Date: 2019-06-03

Lead Sponsor: University of Oxford

Target Recruit Count: 16

Registration Number: NCT02546544

Locations: 🇳🇱
Department of Clinical Oncology, Leiden University Medical Center, Leiden, Postzone K1-P, Netherlands
🇮🇹
Istituti Ortopedici Rizzoli, Bologna, Italy
🇫🇷
Universitè Lyon 1 Claude Bernard, Lyon, France

and more 2 locations

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

Phase 1

Terminated

Conditions: Tuberculosis

Interventions: Biological: Aerosol inhaled MVA85A
Biological: Intramuscular MVA85A
Biological: Intramuscular Saline placebo
Biological: Aerosol inhaled Saline placebo

First Posted Date: 2015-08-25

Last Posted Date: 2020-08-31

Lead Sponsor: University of Oxford

Target Recruit Count: 2

Registration Number: NCT02532036

Locations: 🇬🇧
NIHR/Wellcome Trust King's Clinical Research Facility, London, United Kingdom
🇬🇧
Royal Free Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford, Oxfordshire, United Kingdom

and more 2 locations

A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: ChAd63 Pfs25-IMX313
Biological: MVA Pfs25-IMX313

First Posted Date: 2015-08-25

Last Posted Date: 2017-07-17

Lead Sponsor: University of Oxford

Target Recruit Count: 26

Registration Number: NCT02532049

Locations: 🇬🇧
CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom
🇬🇧
NIHR Wellcome Trust Clinical Research Facility, Southampton, United Kingdom

ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: MF59 - ATIV

First Posted Date: 2015-08-20

Last Posted Date: 2023-12-07

Lead Sponsor: University of Oxford

Target Recruit Count: 120

Registration Number: NCT02529904

Locations: 🇬🇧
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Oxford, United Kingdom

Giant Cell Arteritis: Improving Use of Ultrasound Evaluation

Conditions: Giant Cell Arteritis

Interventions: Device: Ultrasound of temporal and axillary arteries

First Posted Date: 2015-08-14

Last Posted Date: 2015-08-14

Lead Sponsor: University of Oxford

Target Recruit Count: 250

Registration Number: NCT02523625

MEK and MET Inhibition in Colorectal Cancer

Phase 1

Completed

Conditions: Solid Tumor
Colorectal Cancer

Interventions: Drug: PF-02341066
Drug: PD-0325901
Drug: Binimetinib

First Posted Date: 2015-07-28

Last Posted Date: 2021-07-13

Lead Sponsor: University of Oxford

Target Recruit Count: 82

Registration Number: NCT02510001

Locations: 🇬🇧
Oxford University Hospital NHS Trust, Oxford, United Kingdom

Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?

Conditions: Vasculitis
Arthritis

First Posted Date: 2015-07-15

Last Posted Date: 2017-08-02

Lead Sponsor: University of Oxford

Target Recruit Count: 85

Registration Number: NCT02498808

Locations: 🇬🇧
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

Phase 1

Completed

Conditions: Ebola Virus Disease

Interventions: Biological: ChAd3-EBO-Z
Biological: Ad26.ZEBOV

First Posted Date: 2015-07-13

Last Posted Date: 2018-04-11

Lead Sponsor: University of Oxford

Target Recruit Count: 32

Registration Number: NCT02495246

Locations: 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy